Observational Study Comparing Deucravacitinib and Apremilast in Adults With Plaque Psoriasis in North America

What this Trial Is About

Researchers are evaluating the comparative effectiveness of two drugs, deucravacitinib and apremilast, in adults with plaque psoriasis. This observational study aims to understand how these treatments perform in real-world settings to help improve management of plaque psoriasis. The study is sponsored by Bristol-Myers Squibb and focuses on adults who have recently started treatment with either drug. Participants are grouped based on the treatment they have initiated one group taking deucravacitinib and another taking apremilast. Each medication is prescribed by the participants clinician as part of their regular care. The study observes participants for up to 60 months, tracking changes over time while participants remain on their prescribed treatment or until they discontinue. During the study, participants will have assessments at baseline and every six months, including measurements of body surface area affected by psoriasis, investigator global assessment, and quality of life using the Dermatology Life Quality Index. Researchers will also monitor treatment continuation time and various psoriasis severity scores. This long-term follow-up aims to capture comprehensive data on treatment effects and participant well-being throughout the study period.

A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis